Stella Pharma Corporation

4888

JP3399680002

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
292 ^JPY	+0.69%		+5.42%	+2.46%

Feb. 13	Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024	CI
2023	Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024	CI

Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024

August 08, 2023 at 02:20 am EDT

Stella Pharma Corporation provided earnings guidance for the fiscal year ending March 2024. For the period, the company expects net sales to be JPY 269 million, operating loss to be JPY 1,314 million, loss to be JPY 1,327 million and basic loss per share to be JPY 44.28.

Latest news about Stella Pharma Corporation

Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024	Feb. 13	CI
Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024	23-08-08	CI
Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024	23-05-09	CI
Stella Pharma Corporation Provides Earnings Guidance for the Full Year Ending March 31, 2023	23-02-10	CI
Stella Pharma Corporation announced that it has received funding from SMBC Nikko Securities Inc.	22-12-29	CI
Stella Pharma Corporation announced that it expects to receive funding from SMBC Nikko Securities Inc.	22-12-13	CI
Stella Pharma Corporation Provides Earnings Guidance for the Year Ending March 31, 2023	22-11-09	CI
Mizuho Securities Co., Ltd. acquired unknown minority stake in Stella Pharma Corporation from INCJ, Ltd.	22-10-31	CI
Certain Common Stock of Stella Pharma Corporation are subject to a Lock-Up Agreement Ending on 18-OCT-2021.	21-10-17	CI
Certain Common Stock of Stella Pharma Corporation are subject to a Lock-Up Agreement Ending on 20-JUL-2021.	21-07-19	CI
Stella Pharma Corporation has completed an IPO in the amount of ¥3.400044 billion.	21-04-21	CI
Stella Pharma Corporation has filed an IPO in the amount of ¥3.769614 billion.	21-03-19	CI
Stella Pharma Corporation announced that it has received ¥3.6 billion in funding from Sumitomo Heavy Industries, Ltd., Innovation Network Corporation of Japan	16-03-24	CI
Stella Pharma Corporation announced that it expects to receive ¥3.6 billion in funding from Sumitomo Heavy Industries, Ltd., Innovation Network Corporation of Japan	16-03-23	CI

Chart Stella Pharma Corporation

Duration

Period

More charts

Company Profile

Stella Pharma Corp is a Japan-based company mainly engaged in the therapeutic drug research and development. It is engaged in the research and development of boron drugs for boron neutron capture therapy (BNCT). BNCT is a radiation therapy that selectively destroys cancer cells by utilizing the fission reaction of B-10, which is a stable isotope of boron, and thermal neutrons with low energy. Nucleus of B-10, which is a stable isotope of boron, absorbs low-energy low-speed neutrons and immediately splits into a helium nucleus (4He nucleus (Î± particle)) and a lithium nuclei (7Li nuclei). When a substance containing B-10 selectively accumulates in cancer cells and is irradiated with thermal neutrons, cancer cells are selectively destroyed. Product includes steboronin (SPM-011). A phase II clinical trial is conducted for brain tumor, head and neck cancer and recurrent malignant glioma. Phase I clinical trial is started for malignant melanoma, a type of skin cancer, and angiosarcoma.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
STELLA PHARMA CORPORATION	+2.46%	57.92M
ELI LILLY AND COMPANY	+26.47%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.33%	352B
MERCK & CO., INC.	+19.35%	332B
ABBVIE INC.	+4.23%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.04%	145B